Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of Coherus Biosciences (NASDAQ: CHRS) but cut his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE